R. B. Simonson

Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single‐Tablet Regimen

Kevin B. McKenney, H. Crauwels, R. Nettles, 2018, Clinical pharmacology in drug development.

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study

R. Bolan, M. Ramgopal, R. Nettles, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis

Shubin Sheng, H. Hardy, K. Dunn, 2021, HIV research & clinical practice.

Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.

J. Lindenmayer, L. Alphs, N. Schooler, 2015, The Journal of clinical psychiatry.

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder

J. Lindenmayer, L. Alphs, N. Schooler, 2016, Journal of clinical psychopharmacology.

Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.

J. Lindenmayer, L. Alphs, N. Schooler, 2015, The Journal of clinical psychiatry.